Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A.

[1]  J. Overbaugh,et al.  Improved HIV-positive infant survival is correlated with high levels of HIV-specific ADCC activity in multiple cohorts , 2021, Cell reports. Medicine.

[2]  M. Ait-goughoulte,et al.  Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers , 2020, The Journal of experimental medicine.

[3]  I. Barr,et al.  Fc functional antibody responses to adjuvanted versus unadjuvanted seasonal influenza vaccination in community-dwelling older adults. , 2020, Vaccine.

[4]  R. Hammond,et al.  Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[5]  P. Marcellin,et al.  ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg‐positive chronic hepatitis B , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[6]  B. McMahon,et al.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.

[7]  G. Lauer,et al.  ADCC-Mediated CD56DIM NK Cell Responses Are Associated with Early HBsAg Clearance in Acute HBV Infection , 2018, Pathogens & immunity.

[8]  Gustaf E. Rydell,et al.  Hepatitis B surface antigen on subviral particles reduces the neutralizing effect of anti-HBs antibodies on hepatitis B viral particles in vitro. , 2017, Virology.

[9]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[10]  S. Kent,et al.  Dimeric Fcγ Receptor Enzyme-Linked Immunosorbent Assay To Study HIV-Specific Antibodies: A New Look into Breadth of Fcγ Receptor Antibodies Induced by the RV144 Vaccine Trial , 2017, The Journal of Immunology.

[11]  T. Liang,et al.  Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. , 2017, Gastroenterology.

[12]  Reza Assadi,et al.  The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 , 2016, The Lancet.

[13]  Y. Wen,et al.  Immunoregulatory functions of immune complexes in vaccine and therapy , 2016, EMBO molecular medicine.

[14]  S. Kent,et al.  Dimeric FcγR Ectodomains as Probes of the Fc Receptor Function of Anti-Influenza Virus IgG , 2016, The Journal of Immunology.

[15]  Louise A. Carolan,et al.  Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine , 2016, Journal of Virology.

[16]  Simon A. Jones,et al.  Ectopic lymphoid follicles: inducible centres for generating antigen‐specific immune responses within tissues , 2015, Immunology.

[17]  B. McMahon,et al.  Present and future therapies of hepatitis B: From discovery to cure , 2015, Hepatology.

[18]  Y. Liaw,et al.  Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. , 2014, Journal of hepatology.

[19]  M. Yuen,et al.  Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Petric,et al.  Experimental Hbsag/Anti-Hbs Complex Assay for Prediction of Hbeag Loss in Chronic Hepatitis B Patients Treated with Pegylated Interferon and Adefovir , 2014, Antiviral therapy.

[21]  Y. Wen,et al.  Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. , 2013, Journal of hepatology.

[22]  O. Shibolet,et al.  Immunosuppression and HBV Reactivation , 2013, Seminars in Liver Disease.

[23]  R. Simon,et al.  B cell gene signature with massive intrahepatic production of antibodies to hepatitis B core antigen in hepatitis B virus–associated acute liver failure , 2010, Proceedings of the National Academy of Sciences.

[24]  Zheng-hong Yuan,et al.  A Randomized Controlled Phase IIb Trial of Antigen-Antibody Immunogenic Complex Therapeutic Vaccine in Chronic Hepatitis B Patients , 2008 .

[25]  V. Bruss.  Hepatitis B virus morphogenesis. , 2007, World journal of gastroenterology.

[26]  R. Perrillo.  Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. , 2001, Gastroenterology.

[27]  T. Takahara,et al.  Functional B‐cell response in intrahepatic lymphoid follicles in chronic hepatitis C , 1999, Hepatology.

[28]  M. Otto,et al.  Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication , 1997, Antimicrobial agents and chemotherapy.

[29]  C. Chu,et al.  Membrane staining for hepatitis B surface antigen on hepatocytes: a sensitive and specific marker of active viral replication in hepatitis B. , 1995, Journal of clinical pathology.

[30]  K. Koike,et al.  The serology of chronic hepatitis B infection revisited. , 1993, The Journal of clinical investigation.

[31]  W. Gerlich,et al.  Analysis of viral proteins in circulating immune complexes from chronic carriers of hepatitis B virus. , 1991, Clinical and experimental immunology.

[32]  E. Celis,et al.  Antibodies to hepatitis B surface antigen potentiate the response of human T lymphocyte clones to the same antigen. , 1984, Science.

[33]  C R Howard,et al.  Chronic liver disease: the detection and characterization of circulating immune complexes. , 1983, Immunology.

[34]  N. Anh-Tuan,et al.  Hepatitis B surface antigen circulating immune complexes (HBsAg-CICs) in patients with hepatitis B and asymptomatic HBsAg carriers. , 1981, Clinical and experimental immunology.

[35]  C. Chu,et al.  Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis. , 1987, Gastroenterology.